期刊论文详细信息
JOURNAL OF CONTROLLED RELEASE 卷:262
Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo
Article
Ostrem, Ragnhild Garborg1  Parhamifar, Ladan1  Pourhassan, Houman1  Clergeaud, Gael1  Nielsen, Ole Lerberg2  Kjaer, Andreas3  Hansen, Anders Elias1,3  Andresen, Thomas Lars1 
[1] Tech Univ Denmark, Dept Micro & Nanotechnol, Ctr Nanomed & Theranost, DK-2800 Lyngby, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, Ridebanevej 3, DK-1870 Frederiksberg C, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Cluster Mol Imaging, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark
关键词: Secretory phospholipase A(2);    Liposome;    Triggered release;    Cancer therapy;    Drug delivery;    Oxaliplatin;   
DOI  :  10.1016/j.jconrel.2017.07.031
来源: Elsevier
PDF
【 摘 要 】

The clinical use of liposomal drug delivery vehicles is often hindered by insufficient drug release. Here we present the rational design of liposomes optimized for secretory phospholipase A(2) (sPLA(2)) triggered drug release, and test their utility in vitro and in vivo. We hypothesized that by adjusting the level of cholesterol in anionic, unsaturated liposomes we could tune the enzyme specificity based on membrane fluidity, thus obtaining liposomes with an improved therapeutic outcome and reduced side effects. Cholesterol is generally important as a component in the membranes of liposome drug delivery systems due to its stabilizing effects in vivo. The incorporation of cholesterol in sPLA(2) sensitive liposomes has not previously been possible due to reduced sPLA(2) activity. However, in the present work we solved this challenge by optimizing membrane fluidity. In vitro release studies revealed enzyme specific drug release. Treatment of two different cancer cell lines with liposomal oxaliplatin revealed efficient growth inhibition compared to that of clinically used stealth liposomes. The in vivo therapeutic effect was evaluated in nude NMRI mice using the sPLA(2) secreting mammary carcinoma cell line MT-3. Three days after first treatment all mice having received the novel sPLA(2) sensitive liposome formulation were euthanized due to severe systemic toxicity. Thus the present study demonstrates that great caution should be implemented when utilizing sPLA(2) sensitive liposomes and that the real utility can only be disclosed in vivo. The present studies have clinical implications, as sPLA(2) sensitive formulations are currently undergoing clinical trials (LiPlaCis (R)).

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jconrel_2017_07_031.pdf 1060KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:0次